Can We Predict Response to Antidepressants?: Page 2 of 2
Can We Predict Response to Antidepressants?: Page 2 of 2
The genetics of SERT have been studied at length as a predictor of treatment response in MDD. Several groups have found that depressed patients with a certain genetic variant of SERT respond more favorably to SSRIs,19 although this finding has not been replicated in all studies.19, 20 This genetic variant may be independent of SERT binding,21 so that to the extent that each of these measures is predictive of outcome individually, they may have greater predictive power when taken together.
Therefore, it seems that patients who have elevated 5-HT1A receptor binding and decreased SERT binding are less likely to achieve remission with antidepressant treatment, whereas patients whose 5-HT1A receptor and SERT binding are more like those of healthy controls are more likely to achieve remission with treatment. This profile of elevated 5-HT1A binding and decreased SERT binding associated with worse outcomes could be at least partially explained by the genetic variant of the 5-HT1A receptor that we described previously. A genetic variant of SERT could contribute independently to the likelihood of remission. A model of how this profile could arise is presented in Figure 1.
Other genetic markers
Several other genes have been examined in pharmacogenetic studies as possible predictors of treatment outcome in MDD. These include polymorphisms in genes that affect drug metabolism, such as cytochrome P-450 2D6; downstream secondary messenger systems in neurons, such as G-proteins; the viability of neurons, such as brain-derived neuro-trophic factor; and neurotransmitter regulation, such as tryptophan hydroxylase 1.22 Whole-genome association studies may be used in the future to compare SNPs across the entire human genome between remitters and nonremitters in response to specific antidepressant treatments.23
PET STUDIES OF BRAIN METABOLISM
PET can be used to measure the relative rate of glucose metabolism, an indirect measure of resting brain activity, with the use of the glucose radioligand [18F]fluorodeoxyglucose (FDG). Regional glucose metabolism has been studied as a predictor of outcome with antidepressant treatment.24 Depressed patients underwent FDG-PET, followed by 6 weeks of medication-based treatment. Glucose metabolism was compared between responders and nonresponders. Those who responded had higher resting glucose metabolism in the rostral anterior cingulate cortex than patients who did not respond. The authors described connections between the rostral anterior cingulate cortex and several other regions in the brain that could be involved in a poorly functioning circuit related to depression. This finding has been replicated in subsequent PET studies,25 indicating the possible importance of the rostral anterior cingulate cortex in the response to antidepressant medications. Another FDG-PET study found the opposite relationship between metabolism and treatment response in the left ventral anterior cingulate cortex, an adjacent brain region.26
fMRI STUDIES OF BRAIN ACTIVITY
A series of fMRI studies have looked at brain activations in response to specific probes as predictors of response to treatment in patients with MDD. In one of the first of these studies, patients viewed pictures of emotionally neutral or charged scenes, and their patterns of brain activation were used to predict subsequent response to the antidepressant venlafaxine.27 The investigators found that larger responses in the anterior cingulate cortex to presentation of emotionally negative pictures were associated with subsequent improvement with venlafaxine treatment, which is consistent with the FDG-PET studies previously described. This finding was recently replicated using responses to emotional faces to predict outcome with fluoxetine treatment.28 Interestingly, that study also analyzed structural MRI scans on the same patients, and found increased gray matter in the anterior cingulate cortex and other regions among fluoxetine responders, suggesting that the changes in brain activity that predict treatment response may reflect underlying differences in brain structure.
A more recent fMRI study looked at brain activation in response to the presentation of emotionally charged words as a predictor of recovery from MDD following CBT.29 It found a specific pattern of brain activity during the viewing of emotionally negative words that was associated with subsequent improvement with CBT: low activation of the subgenual cingulate cortex and high activation of the amygdala. The amygdala is involved in processing emotional stimuli, and its responses to emotional stimuli may be controlled by connections from the subgenual cingulate cortex.30 This finding involving the subgenual cingulate cortex contradicts the 2 fMRI studies involving medication treatment described above. Whether this is because of methodological differences between the studies or, more promisingly, caused by different patterns of cingulate activity predicting differential response to medication versus CBT remains an important question.
From this brief review, we hope to convey a sense of the breadth of approaches that show promise in predicting response to treatments of depression, as well as some of their limitations, including nonstandardized methodology for conducting functional brain imaging scans and conflicting results between studies. The measures we have described in this review are only partially predictive of treatment outcome when used individually.
To address this, we are currently developing statistical models that combine relevant clinical, brain imaging, and genetic data to predict which treatments will be the most effective for a particular patient. Whereas brain imaging studies to date have examined activity or chemistry in relatively large regions of the brain as predictors of treatment outcome, we are using measures of brain activity or chemistry in areas as small as a few cubic millimeters in these models, allowing us to rely less on preconceived notions about the anatomy and organization of the brain.31 In addition to predicting treatment outcome, these models may be used for predicting diagnosis (such as unipolar vs bipolar depression), as well as risk of suicidal behavior. Finally, studies are needed in which multiple biological and clinical measures are obtained before randomization to different standardized treatment conditions in order to bring these techniques closer to being ready for clinical use.
1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using mea-surement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137.
5. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry. 1991; 148:997-1008.
6. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994;40:288-295.
7. Aghajanian GK, Sanders-Bush E. Serotonin. In: Davis KL, Charney D, Coyle JT, Nemiroff C, eds. Neuropsycho-pharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins; 2002. Available at: http://www.acnp.org/default.aspx?Page=5thGenerationChapters. Accessed August 22, 2007.
8. Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23:8788-8799.
9. Albert PR. A functional promoter polymorphism of the 5-HT1A receptor gene: association with depression and completed suicide. Biol Psychiatry. 2004;55:46S.
10. Lemonde S, Du L, Bakish D, et al. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol. 2004;7:501-506.
11. Serretti A, Artioli P, Lorenzi C, et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol. 2004;7:453-460.
12. Arias B, Catalan R, Gasto C, et al. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psycho-pharmacol. 2005;19:166-172.
13. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry. 1990;51:14-20.
14. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106-113.
15. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta. 1993;1144:249-263.
16. Parsey RV, Olvet DM, Oquendo MA, et al. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsycho-pharmacology. 2006;31:1745-1749.
17. Parsey RV, Hastings RS, Oquendo MA, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry. 2006;163:52-58.
18. Kugaya A, Sanacora G, Staley JK, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry. 2004;56:497-502.
19. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1062-1073.
20. Kraft JB, Peters EJ, Slager SL, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry. 2007;61:734-742.
21. Parsey RV, Hastings RS, Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry. 2006;163:48-51.
22. Bondy B. Pharmacogenomics in depression and antidepressants. Dialogues Clin Neurosci. 2005;7:223-230.
23. Motsinger AA, Ritchie MD, Dobrin SE. Clinical applications of whole-genome association studies: future applications at the bedside. Expert Rev Mol Diagn. 2006; 6:551-565.
24. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057-1061.
25. Saxena S, Brody AL, Ho ML, et al. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry. 2003;160:522-532.
26. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 1999;91: 127-139.
27. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry. 2003; 160:64-75.
28. Chen CH, Ridler K, Suckling J, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. Jan 8, 2007; [Epub ahead of print].
29. Siegle GJ, Carter CS, Thase ME. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry. 2006;163:735-738.
30. Ghashghaei HT, Barbas H. Pathways for emotion: interactions of prefrontal and anterior temporal pathways in the amygdala of the rhesus monkey. Neuroscience. 2002;115:1261-1279.
31. Reiss PT. Regression With Signals and Images as Predictors. New York: Doctoral thesis in the Department of Biostatistics, Columbia University; 2006.